A Phase 4 interventional study of 13vPnC in Vaccines, sponsored by Pfizer. Completed at 7 sites in India. Open to participants aged 42 Days to 72 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-30.
Sponsored by Pfizer · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase 4 Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India
A Phase 4, Randomized, Open-label Trial To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Infant who is a direct descendant (child, grandchild) of
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multi Dose Vial with preservative
Biological: 13vPnC
Pre Filled Syringe without preservative
Biological: 13vPnC
13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 centimeters \[cm\]), moderate (2.5 to 7.0 cm) and, severe (greater than \[\>\] 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.
Time frame: Within 7 days after Vaccination 1
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability,were recorded daily using an electronic diary. Fever graded as:1)less than (\<)38.0 degrees Celsius \[C\], 2)greater than or equal to(\>=)38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as:mild(increased or prolonged sleeping bouts), moderate(slightly subdued; interfering with daily activity), and severe(disabling; not interested in usual daily activity). Irritability graded as: mild(easily consolable), moderate(required increased attention), and severe(inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here,"Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.
Time frame: Within 7 days after Vaccination 1
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 cm), moderate (2.5 to 7.0 cm) and, severe (\> 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.
Time frame: Within 7 days after Vaccination 2
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability, were recorded daily using an electronic diary. Fever graded as:1) \< 38.0 degrees C, 2) \>= 38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as: mild (increased or prolonged sleeping bouts), moderate (slightly subdued; interfering with daily activity), and severe (disabling; not interested in usual daily activity). Irritability graded as: mild (easily consolable), moderate (required increased attention), and severe (inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here, "Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.
Time frame: Within 7 days after Vaccination 2
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 3
Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 cm), moderate (2.5 to 7.0 cm) and, severe (\> 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.
Time frame: Within 7 days after Vaccination 3
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 3
Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability, were recorded daily using an electronic diary. Fever graded as:1) \< 38.0 degrees C, 2) \>= 38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as: mild (increased or prolonged sleeping bouts), moderate (slightly subdued; interfering with daily activity), and severe (disabling; not interested in usual daily activity). Irritability graded as: mild (easily consolable), moderate (required increased attention), and severe (inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here, "Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.
Time frame: Within 7 days after Vaccination 3
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 4
Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 cm), moderate (2.5 to 7.0 cm) and, severe (\> 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.
Time frame: Within 7 days after Vaccination 4
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 4
Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability, were recorded daily using an electronic diary. Fever graded as:1) \< 38.0 degrees C, 2) \>= 38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as: mild (increased or prolonged sleeping bouts), moderate (slightly subdued; interfering with daily activity), and severe (disabling; not interested in usual daily activity). Irritability graded as: mild (easily consolable), moderate (required increased attention), and severe (inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here, "Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.
Time frame: Within 7 days after Vaccination 4
Percentage of Participants With Adverse Events (AEs) After Vaccination 1 up to 1 Month After Vaccination 3
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship.
Time frame: From Vaccination 1 up to 1 Month after Vaccination 3 (for a maximum study duration of 3 months)
Percentage of Participants With Adverse Events (AEs) From Vaccination 4 up to 1 Month After Vaccination 4
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship.
Time frame: From Vaccination 4 up to 1 month after Vaccination 4 (for a maximum study duration of 1 month)
Percentage of Participants With Serious Adverse Events (SAEs) After Vaccination 1 up to 1 Month After Vaccination 4
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: From Vaccination 1 up to 1 month after Vaccination 4 (for a maximum study duration of 11.5 months)
Number of Participants With New Diagnosed Chronic Medical Condition (NDCMC) From 1 Month After Vaccination 3 up to Vaccination 4
A newly diagnosed chronic medical condition was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: From 1 month after Vaccination 3 up to Vaccination 4 (for a maximum study duration of 7.5 months)
Percentage of Participants With Immunoglobulin G (IgG) Concentrations Greater Than or Equal to (>=) Pre-defined Thresholds for Each of the Pneumococcal Serotypes Measured 1 Month After Vaccination 3
Percentage of participants achieving predefined antibody threshold: \>=0.35 microgram per milliliter (mcg/mL) for the 10 pneumococcal serotypes 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F and 23F; threshold \>= 0.23 mcg/mL for serotype 5, threshold \>= 0.10 mcg/mL for serotype 6B, threshold \>= 0.12 mcg/mL for serotype 19A, along with the corresponding 95 percent (%) confidence interval (CI) are reported.
Time frame: 1 month after Vaccination 3
Percentage of Participants With Immunoglobulin G (IgG) Concentrations Greater Than or Equal to (>=) Pre-defined Thresholds for Each of the Pneumococcal Serotypes Measured 1 Month After Vaccination 4
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL for the 10 pneumococcal serotypes 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F and 23F, threshold \>= 0.23 mcg/mL for serotype 5, threshold \>= 0.10 mcg/mL for serotype 6B, threshold \>= 0.12 mcg/mL for serotype 19A, along with the corresponding 95% CI are reported.
Time frame: 1 month after Vaccination 4
Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 3
Antibody (IgG) GMCs for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) and corresponding 2-sided 95% CI are reported.
Time frame: 1 month after Vaccination 3
Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 4
Antibody (IgG) GMCs for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) and corresponding 2-sided 95% CI are reported.
Time frame: 1 month after Vaccination 4
Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 3
Antibody-mediated serum OPA against the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a pneumococcal OPA assay. Initial results were measured as OPA titers, which were then logarithmically transformed for analysis; geometric means calculated and expressed as GMTs.
Time frame: 1 month after Vaccination 3
Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 4
Antibody-mediated serum OPA against the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a pneumococcal OPA assay. Initial results were measured as OPA titers, which were then logarithmically transformed for analysis; geometric means calculated and expressed as GMTs.
Time frame: 1 month after Vaccination 4
Percentage of Participants With Opsonophagocytic Activity (OPA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 3
Percentage of participants achieving OPA titer \>=LLOQ along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of participants was presented. LLOQ (measured in mcg/mL) for each serotype is as follows: Serotype 1=18; Serotype 3=12; Serotype 4=21; Serotype 5=29; Serotype 6A=37; Serotype 6B=43; Serotype 7F=113; Serotype 9V=141; Serotype 14=35; Serotype 18C=31; Serotype 19A=18; Serotype 19F=48; Serotype 23F=13.
Time frame: 1 month after Vaccination 3
Percentage of Participants With Opsonophagocytic Activity (OPA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of Pneumococcal Serotypes Measured 1 Month After Vaccination 4
Percentage of participants achieving OPA titer \>=LLOQ along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of participants was presented. LLOQ (measured in mcg/mL) for each serotype is as follows: Serotype 1=18; Serotype 3=12; Serotype 4=21; Serotype 5=29; Serotype 6A=37; Serotype 6B=43; Serotype 7F=113; Serotype 9V=141; Serotype 14=35; Serotype 18C=31; Serotype 19A=18; Serotype 19F=48; Serotype 23F=13.
Time frame: 1 month after Vaccination 4
| Milestone | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Started | 151 | 150 |
| Vaccination 1 | 150 | 150 |
| Vaccination 2 | 144 | 144 |
| Vaccination 3 | 144 | 141 |
| Completed | 139 | 139 |
| Not completed | 12 | 11 |
| Withdrew: Withdrawal by parent/guardian | 8 | 8 |
| Withdrew: No longer met eligibility criteria | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Randomized but not vaccinated | 1 | 0 |
| Milestone | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Started | 139 | 139 |
| Vaccination 4 | 139 | 139 |
| Completed | 138 | 138 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by parent/guardian | 1 | 1 |
Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 centimeters \[cm\]), moderate (2.5 to 7.0 cm) and, severe (greater than \[\>\] 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Redness: Any | 19.7 (13.6 to 27.1) | 16.9 (11.2 to 23.9) |
| Redness: Mild | 17.7 (11.9 to 24.8) | 12.8 (7.9 to 19.3) |
| Redness: Moderate | 2.0 (0.4 to 5.8) | 4.1 (1.5 to 8.6) |
| Redness: Severe | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Swelling: Any | 27.9 (20.8 to 35.9) | 33.8 (26.2 to 42.0) |
| Swelling: Mild | 21.8 (15.4 to 29.3) | 23.6 (17.1 to 31.3) |
| Swelling: Moderate | 6.1 (2.8 to 11.3) | 10.1 (5.8 to 16.2) |
| Swelling: Severe | 0 (0.0 to 2.5) | 0 (0.0 to 2.5) |
| Pain at injection site: Any | 61.9 (53.5 to 69.8) | 67.6 (59.4 to 75.0) |
| Pain at injection site: Mild | 28.6 (21.4 to 36.6) | 33.1 (25.6 to 41.3) |
| Pain at injection site: Moderate | 30.6 (23.3 to 38.7) | 29.1 (21.9 to 37.1) |
| Pain at injection site: Severe | 2.7 (0.7 to 6.8) | 5.4 (2.4 to 10.4) |
Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability,were recorded daily using an electronic diary. Fever graded as:1)less than (\<)38.0 degrees Celsius \[C\], 2)greater than or equal to(\>=)38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as:mild(increased or prolonged sleeping bouts), moderate(slightly subdued; interfering with daily activity), and severe(disabling; not interested in usual daily activity). Irritability graded as: mild(easily consolable), moderate(required increased attention), and severe(inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here,"Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Fever: <38.0 degree C | 15.0 (9.6 to 21.8) | 10.8 (6.3 to 17.0) |
| Fever: >=38.0 degree C to 38.4 degree C | 10.9 (6.4 to 17.1) | 8.1 (4.3 to 13.7) |
| Fever: 38.5 degree C to 38.9 degree C | 1.4 (0.2 to 4.8) | 2.7 (0.7 to 6.8) |
| Fever: 39.0 degree C to 40.0 degree C | 1.4 (0.2 to 4.8) | 0 (0.0 to 2.5) |
| Fever: >40.0 degree C | 1.4 (0.2 to 4.8) | 0 (0.0 to 2.5) |
| Decreased appetite: Any | 42.2 (34.1 to 50.6) | 53.4 (45.0 to 61.6) |
| Decreased appetite: Mild | 23.8 (17.2 to 31.5) | 30.4 (23.1 to 38.5) |
| Decreased appetite: Moderate | 17.7 (11.9 to 24.8) | 21.6 (15.3 to 29.1) |
| Decreased appetite: Severe | 0.7 (0.0 to 3.7) | 1.4 (0.2 to 4.8) |
| Drowsiness: Any | 55.1 (46.7 to 63.3) | 66.2 (58.0 to 73.8) |
| Drowsiness: Mild | 29.3 (22.0 to 37.3) | 33.1 (25.6 to 41.3) |
| Drowsiness: Moderate | 25.2 (18.4 to 33.0) | 31.1 (23.7 to 39.2) |
| Drowsiness: Severe | 0.7 (0.0 to 3.7) | 2.0 (0.4 to 5.8) |
| Irritability: Any | 64.6 (56.3 to 72.3) | 65.5 (57.3 to 73.2) |
| Irritability: Mild | 37.4 (29.6 to 45.8) | 32.4 (25.0 to 40.6) |
| Irritability: Moderate | 21.8 (15.4 to 29.3) | 26.4 (19.5 to 34.2) |
| Irritability: Severe | 5.4 (2.4 to 10.4) | 6.8 (3.3 to 12.1) |
Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 cm), moderate (2.5 to 7.0 cm) and, severe (\> 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Redness: Any | 17.0 (11.2 to 24.3) | 19.3 (13.1 to 26.8) |
| Redness: Mild | 16.3 (10.6 to 23.5) | 17.9 (11.9 to 25.2) |
| Redness: Moderate | 0.7 (0.0 to 3.9) | 1.4 (0.2 to 5.1) |
| Redness: Severe | 0 (0.0 to 2.6) | 0 (0.0 to 2.6) |
| Swelling: Any | 24.8 (17.9 to 32.8) | 27.9 (20.6 to 36.1) |
| Swelling: Mild | 21.3 (14.8 to 29.0) | 22.9 (16.2 to 30.7) |
| Swelling: Moderate | 3.5 (1.2 to 8.1) | 5.0 (2.0 to 10.0) |
| Swelling: Severe | 0 (0.0 to 2.6) | 0 (0.0 to 2.6) |
| Pain at injection site: Any | 59.6 (51.0 to 67.7) | 62.1 (53.6 to 70.2) |
| Pain at injection site: Mild | 32.6 (25.0 to 41.0) | 29.3 (21.9 to 37.6) |
| Pain at injection site: Moderate | 20.6 (14.2 to 28.2) | 26.4 (19.3 to 34.5) |
| Pain at injection site: Severe | 6.4 (3.0 to 11.8) | 6.4 (3.0 to 11.9) |
Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability, were recorded daily using an electronic diary. Fever graded as:1) \< 38.0 degrees C, 2) \>= 38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as: mild (increased or prolonged sleeping bouts), moderate (slightly subdued; interfering with daily activity), and severe (disabling; not interested in usual daily activity). Irritability graded as: mild (easily consolable), moderate (required increased attention), and severe (inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here, "Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Fever: <38.0 degree C | 8.5 (4.5 to 14.4) | 8.6 (4.5 to 14.5) |
| Fever: >=38.0 degree C to 38.4 degree C | 6.4 (3.0 to 11.8) | 5.7 (2.5 to 10.9) |
| Fever: 38.5 degree C to 38.9 degree C | 2.1 (0.4 to 6.1) | 2.1 (0.4 to 6.1) |
| Fever: 39.0 degree C to 40.0 degree C | 0 (0.0 to 2.6) | 0 (0.0 to 2.6) |
| Fever: >40.0 degree C | 0 (0.0 to 2.6) | 0.7 (0.0 to 3.9) |
| Decreased appetite: Any | 40.4 (32.3 to 49.0) | 38.6 (30.5 to 47.2) |
| Decreased appetite: Mild | 27.0 (19.8 to 35.1) | 25.0 (18.1 to 33.0) |
| Decreased appetite: Moderate | 12.1 (7.2 to 18.6) | 12.1 (7.2 to 18.7) |
| Decreased appetite: Severe | 1.4 (0.2 to 5.0) | 1.4 (0.2 to 5.1) |
| Drowsiness: Any | 50.4 (41.8 to 58.9) | 52.1 (43.5 to 60.7) |
| Drowsiness: Mild | 23.4 (16.7 to 31.3) | 22.1 (15.6 to 29.9) |
| Drowsiness: Moderate | 25.5 (18.6 to 33.6) | 26.4 (19.3 to 34.5) |
| Drowsiness: Severe | 1.4 (0.2 to 5.0) | 3.6 (1.2 to 8.1) |
| Irritability: Any | 56.7 (48.1 to 65.0) | 60.0 (51.4 to 68.2) |
| Irritability: Mild | 29.1 (21.7 to 37.3) | 37.9 (29.8 to 46.4) |
| Irritability: Moderate | 24.8 (17.9 to 32.8) | 17.9 (11.9 to 25.2) |
| Irritability: Severe | 2.8 (0.8 to 7.1) | 4.3 (1.6 to 9.1) |
Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 cm), moderate (2.5 to 7.0 cm) and, severe (\> 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Redness: Any | 20.1 (13.8 to 27.8) | 22.9 (16.2 to 30.7) |
| Redness: Mild | 20.1 (13.8 to 27.8) | 20.0 (13.7 to 27.6) |
| Redness: Moderate | 0 (0.0 to 2.6) | 2.9 (0.8 to 7.2) |
| Redness: Severe | 0 (0.0 to 2.6) | 0 (0.0 to 2.6) |
| Swelling: Any | 23.0 (16.3 to 30.9) | 27.1 (20.0 to 35.3) |
| Swelling: Mild | 20.9 (14.4 to 28.6) | 23.6 (16.8 to 31.5) |
| Swelling: Moderate | 2.2 (0.4 to 6.2) | 2.9 (0.8 to 7.2) |
| Swelling: Severe | 0 (0.0 to 2.6) | 0.7 (0.0 to 3.9) |
| Pain at injection site: Any | 55.4 (46.7 to 63.8) | 54.3 (45.7 to 62.7) |
| Pain at injection site: Mild | 30.2 (22.7 to 38.6) | 27.9 (20.6 to 36.1) |
| Pain at injection site: Moderate | 23.0 (16.3 to 30.9) | 21.4 (14.9 to 29.2) |
| Pain at injection site: Severe | 2.2 (0.4 to 6.2) | 5.0 (2.0 to 10.0) |
Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability, were recorded daily using an electronic diary. Fever graded as:1) \< 38.0 degrees C, 2) \>= 38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as: mild (increased or prolonged sleeping bouts), moderate (slightly subdued; interfering with daily activity), and severe (disabling; not interested in usual daily activity). Irritability graded as: mild (easily consolable), moderate (required increased attention), and severe (inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here, "Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Fever: <38.0 degree C | 7.2 (3.5 to 12.8) | 9.3 (5.0 to 15.4) |
| Fever: >=38.0 degree C to 38.4 degree C | 4.3 (1.6 to 9.2) | 6.4 (3.0 to 11.9) |
| Fever: 38.5 degree C to 38.9 degree C | 2.2 (0.4 to 6.2) | 1.4 (0.2 to 5.1) |
| Fever: 39.0 degree C to 40.0 degree C | 0 (0.0 to 2.6) | 1.4 (0.2 to 5.1) |
| Fever: >40.0 degree C | 0.7 (0.0 to 3.9) | 0 (0.0 to 2.6) |
| Decreased appetite: Any | 34.5 (26.7 to 43.1) | 36.4 (28.5 to 45.0) |
| Decreased appetite: Mild | 20.1 (13.8 to 27.8) | 23.6 (16.8 to 31.5) |
| Decreased appetite: Moderate | 11.5 (6.7 to 18.0) | 10.0 (5.6 to 16.2) |
| Decreased appetite: Severe | 2.9 (0.8 to 7.2) | 2.9 (0.8 to 7.2) |
| Drowsiness: Any | 36.0 (28.0 to 44.5) | 39.3 (31.1 to 47.9) |
| Drowsiness: Mild | 20.9 (14.4 to 28.6) | 19.3 (13.1 to 26.8) |
| Drowsiness: Moderate | 13.7 (8.4 to 20.5) | 17.9 (11.9 to 25.2) |
| Drowsiness: Severe | 1.4 (0.2 to 5.1) | 2.1 (0.4 to 6.1) |
| Irritability: Any | 54.7 (46.0 to 63.1) | 60.0 (51.4 to 68.2) |
| Irritability: Mild | 31.7 (24.0 to 40.1) | 37.9 (29.8 to 46.4) |
| Irritability: Moderate | 19.4 (13.2 to 27.0) | 15.7 (10.1 to 22.8) |
| Irritability: Severe | 3.6 (1.2 to 8.2) | 6.4 (3.0 to 11.9) |
Local reactions were recorded daily using an electronic diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.5 cm), moderate (2.5 to 7.0 cm) and, severe (\> 7 cm). Pain at injection site was graded as mild (hurt if gently touched (example, whimpers, winces, protests, or withdraws), moderate (hurt if gently touched \[with crying\]), and severe (caused limitation of limb movement). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling and pain at injection site represents any grade of these local reactions among mild, moderate or severe.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Redness: Any | 8.3 (4.2 to 14.4) | 11.4 (6.5 to 18.0) |
| Redness: MIld | 8.3 (4.2 to 14.4) | 10.6 (5.9 to 17.2) |
| Redness: Moderate | 0 (0.0 to 2.8) | 0.8 (0.0 to 4.1) |
| Redness: Severe | 0 (0.0 to 2.8) | 0 (0.0 to 2.8) |
| Swelling: Any | 9.1 (4.8 to 15.3) | 12.1 (7.1 to 18.9) |
| Swelling: Mild | 6.8 (3.2 to 12.5) | 11.4 (6.5 to 18.0) |
| Swelling: Moderate | 2.3 (0.5 to 6.5) | 0.8 (0.0 to 4.1) |
| Swelling: Severe | 0 (0.0 to 2.8) | 0 (0.0 to 2.8) |
| Pain at injection site: Any | 25.0 (17.9 to 33.3) | 19.7 (13.3 to 27.5) |
| Pain at injection site: Mild | 18.9 (12.6 to 26.7) | 13.6 (8.3 to 20.7) |
| Pain at injection site: Moderate | 6.1 (2.7 to 11.6) | 5.3 (2.2 to 10.6) |
| Pain at injection site: Severe | 0 (0.0 to 2.8) | 0.8 (0.0 to 4.1) |
Systemic events included fever, decreased appetite, drowsiness(increased sleep) and irritability, were recorded daily using an electronic diary. Fever graded as:1) \< 38.0 degrees C, 2) \>= 38.0 degree C to 38.4 degree C, 3)38.5 degree C to 38.9 degree C, 4) 39.0 degree C to 40.0 degree C, 5) \>40.0 degree C. Decreased appetite graded as: mild(decreased interest in eating), moderate(decreased oral intake), and severe(refusal to feed). Drowsiness graded as: mild (increased or prolonged sleeping bouts), moderate (slightly subdued; interfering with daily activity), and severe (disabling; not interested in usual daily activity). Irritability graded as: mild (easily consolable), moderate (required increased attention), and severe (inconsolable; crying could not be comforted). Participants may be represented in \>1 row. Here, "Any" for decreased appetite, drowsiness, irritability represents any grade of these systemic reactions among mild, moderate or severe.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Fever: <38.0 degree C | 3.0 (0.8 to 7.6) | 4.5 (1.7 to 9.6) |
| Fever: >=38.0 degree C to 38.4 degree C | 1.5 (0.2 to 5.4) | 3.8 (1.2 to 8.6) |
| Fever: 38.5 degree C to 38.9 degree C | 0 (0.0 to 2.8) | 0 (0.0 to 2.8) |
| Fever: 39.0 degree C to 40.0 degree C | 0 (0.0 to 2.8) | 0.8 (0.0 to 4.1) |
| Fever: >40.0 degree C | 1.5 (0.2 to 5.4) | 0 (0.0 to 2.8) |
| Decreased appetite: Any | 15.2 (9.5 to 22.4) | 16.7 (10.7 to 24.1) |
| Decreased appetite: Mild | 10.6 (5.9 to 17.2) | 6.8 (3.2 to 12.5) |
| Decreased appetite: Moderate | 4.5 (1.7 to 9.6) | 9.8 (5.3 to 16.3) |
| Decreased appetite: Severe | 0 (0.0 to 2.8) | 0 (0.0 to 2.8) |
| Drowsiness: Any | 7.6 (3.7 to 13.5) | 18.9 (12.6 to 26.7) |
| Drowsiness: Mild | 3.8 (1.2 to 8.6) | 12.9 (7.7 to 19.8) |
| Drowsiness: Moderate | 3.8 (1.2 to 8.6) | 6.1 (2.7 to 11.6) |
| Drowsiness: Severe | 0 (0.0 to 2.8) | 0 (0.0 to 2.8) |
| Irritability: Any | 24.2 (17.2 to 32.5) | 23.5 (16.5 to 31.6) |
| Irritability: Mild | 15.9 (10.1 to 23.3) | 16.7 (10.7 to 24.1) |
| Irritability: Moderate | 7.6 (3.7 to 13.5) | 5.3 (2.2 to 10.6) |
| Irritability: Severe | 0.8 (0.0 to 4.1) | 1.5 (0.2 to 5.4) |
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) After Vaccination 1 up to 1 Month After Vaccination 3 | 47.3 (39.1 to 55.6) | 49.3 (41.1 to 57.6) |
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Vaccination 4 up to 1 Month After Vaccination 4 | 7.9 (4.0 to 13.7) | 8.6 (4.5 to 14.6) |
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) After Vaccination 1 up to 1 Month After Vaccination 4 | 8.0 (4.2 to 13.6) | 4.7 (1.9 to 9.4) |
A newly diagnosed chronic medical condition was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Number of Participants With New Diagnosed Chronic Medical Condition (NDCMC) From 1 Month After Vaccination 3 up to Vaccination 4 | 0 | 0 |
Percentage of participants achieving predefined antibody threshold: \>=0.35 microgram per milliliter (mcg/mL) for the 10 pneumococcal serotypes 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F and 23F; threshold \>= 0.23 mcg/mL for serotype 5, threshold \>= 0.10 mcg/mL for serotype 6B, threshold \>= 0.12 mcg/mL for serotype 19A, along with the corresponding 95 percent (%) confidence interval (CI) are reported.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Serotype: 1 | 91.2 (85.1 to 95.4) | 85.0 (77.7 to 90.6) |
| Serotype: 3 | 91.9 (86.0 to 95.9) | 85.7 (78.6 to 91.2) |
| Serotype: 4 | 91.2 (85.1 to 95.4) | 91.0 (84.8 to 95.3) |
| Serotype: 5 | 84.6 (77.4 to 90.2) | 82.0 (74.4 to 88.1) |
| Serotype: 6A | 83.8 (76.5 to 89.6) | 71.4 (63.0 to 78.9) |
| Serotype: 6B | 77.2 (69.2 to 84.0) | 75.2 (67.0 to 82.3) |
| Serotype: 7F | 96.3 (91.6 to 98.8) | 93.2 (87.5 to 96.9) |
| Serotype: 9V | 85.3 (78.2 to 90.8) | 83.5 (76.0 to 89.3) |
| Serotype: 14 | 88.2 (81.6 to 93.1) | 82.7 (75.2 to 88.7) |
| Serotype: 18C | 92.6 (86.9 to 96.4) | 84.2 (76.9 to 90.0) |
| Serotype: 19A | 100.0 (97.3 to 100.0) | 98.5 (94.7 to 99.8) |
| Serotype: 19F | 97.8 (93.7 to 99.5) | 95.5 (90.4 to 98.3) |
| Serotype: 23F | 84.6 (77.4 to 90.2) | 76.7 (68.6 to 83.6) |
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL for the 10 pneumococcal serotypes 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F and 23F, threshold \>= 0.23 mcg/mL for serotype 5, threshold \>= 0.10 mcg/mL for serotype 6B, threshold \>= 0.12 mcg/mL for serotype 19A, along with the corresponding 95% CI are reported.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Serotype: 1 | 99.2 (95.9 to 100.0) | 100.0 (97.2 to 100.0) |
| Serotype: 3 | 97.0 (92.4 to 99.2) | 98.4 (94.5 to 99.8) |
| Serotype: 4 | 99.2 (95.9 to 100.0) | 100.0 (97.2 to 100.0) |
| Serotype: 5 | 99.2 (95.9 to 100.0) | 100.0 (97.2 to 100.0) |
| Serotype: 6A | 96.2 (91.4 to 98.8) | 96.9 (92.3 to 99.1) |
| Serotype: 6B | 98.5 (94.6 to 99.8) | 96.9 (92.3 to 99.1) |
| Serotype: 7F | 99.2 (95.9 to 100.0) | 99.2 (95.8 to 100.0) |
| Serotype: 9V | 98.5 (94.6 to 99.8) | 99.2 (95.8 to 100.0) |
| Serotype: 14 | 97.7 (93.5 to 99.5) | 96.1 (91.2 to 98.7) |
| Serotype: 18C | 97.0 (92.4 to 99.2) | 99.2 (95.8 to 100.0) |
| Serotype: 19A | 99.2 (95.9 to 100.0) | 99.2 (95.8 to 100.0) |
| Serotype: 19F | 98.5 (94.6 to 99.8) | 100.0 (97.2 to 100.0) |
| Serotype: 23F | 99.2 (95.9 to 100.0) | 96.9 (92.3 to 99.1) |
Antibody (IgG) GMCs for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) and corresponding 2-sided 95% CI are reported.
| mcg/mL | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Serotype: 1 | 1.36 (1.15 to 1.60) | 1.13 (0.94 to 1.36) |
| Serotype: 3 | 1.01 (0.88 to 1.16) | 0.93 (0.80 to 1.07) |
| Serotype: 4 | 1.67 (1.40 to 1.98) | 1.75 (1.45 to 2.11) |
| Serotype: 5 | 0.83 (0.67 to 1.02) | 0.86 (0.67 to 1.11) |
| Serotype: 6A | 1.45 (1.13 to 1.87) | 0.86 (0.66 to 1.12) |
| Serotype: 6B | 0.41 (0.31 to 0.55) | 0.33 (0.24 to 0.46) |
| Serotype: 7F | 2.01 (1.74 to 2.33) | 1.85 (1.52 to 2.26) |
| Serotype: 9V | 1.42 (1.17 to 1.73) | 1.28 (1.02 to 1.62) |
| Serotype: 14 | 1.66 (1.33 to 2.06) | 1.39 (1.09 to 1.76) |
| Serotype: 18C | 1.81 (1.50 to 2.18) | 1.37 (1.10 to 1.71) |
| Serotype: 19A | 2.33 (1.96 to 2.78) | 1.86 (1.51 to 2.28) |
| Serotype: 19F | 2.89 (2.52 to 3.31) | 2.43 (2.04 to 2.89) |
| Serotype: 23F | 1.48 (1.20 to 1.81) | 0.94 (0.73 to 1.21) |
Antibody (IgG) GMCs for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) and corresponding 2-sided 95% CI are reported.
| mcg/mL | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Serotype: 1 | 4.35 (3.71 to 5.10) | 4.27 (3.65 to 4.99) |
| Serotype: 3 | 1.58 (1.36 to 1.83) | 1.63 (1.43 to 1.86) |
| Serotype: 4 | 10.58 (8.89 to 12.60) | 11.91 (10.19 to 13.93) |
| Serotype: 5 | 5.16 (4.37 to 6.10) | 5.68 (4.81 to 6.70) |
| Serotype: 6A | 18.55 (14.32 to 24.02) | 20.51 (16.32 to 25.78) |
| Serotype: 6B | 11.76 (9.24 to 14.98) | 10.87 (8.14 to 14.53) |
| Serotype: 7F | 7.92 (6.88 to 9.13) | 8.29 (7.17 to 9.57) |
| Serotype: 9V | 8.78 (7.19 to 10.73) | 9.57 (8.00 to 11.44) |
| Serotype: 14 | 13.20 (10.69 to 16.30) | 11.78 (9.31 to 14.90) |
| Serotype: 18C | 6.21 (5.19 to 7.44) | 6.27 (5.25 to 7.48) |
| Serotype: 19A | 12.26 (10.26 to 14.65) | 12.02 (9.75 to 14.82) |
| Serotype: 19F | 13.65 (11.16 to 16.69) | 14.09 (11.71 to 16.96) |
| Serotype: 23F | 10.89 (8.78 to 13.50) | 9.90 (7.75 to 12.66) |
Antibody-mediated serum OPA against the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a pneumococcal OPA assay. Initial results were measured as OPA titers, which were then logarithmically transformed for analysis; geometric means calculated and expressed as GMTs.
| titer (1/dilution) | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Serotype: 1 | 21.8 (18.1 to 26.2) | 22.5 (18.1 to 27.9) |
| Serotype: 3 | 79.7 (68.8 to 92.3) | 72.8 (62.7 to 84.6) |
| Serotype: 4 | 1158.8 (938.3 to 1431.1) | 1159.2 (948.3 to 1417.0) |
| Serotype: 5 | 37.0 (31.4 to 43.5) | 40.9 (34.0 to 49.3) |
| Serotype: 6A | 1211.7 (896.4 to 1638.0) | 1321.9 (1026.7 to 1701.9) |
| Serotype: 6B | 1145.8 (870.4 to 1508.3) | 957.6 (708.2 to 1294.8) |
| Serotype: 7F | 1743.3 (1436.6 to 2115.5) | 1178.8 (952.6 to 1458.6) |
| Serotype: 9V | 643.9 (498.6 to 831.7) | 683.3 (522.6 to 893.3) |
| Serotype: 14 | 496.9 (344.2 to 717.3) | 341.8 (236.0 to 495.0) |
| Serotype: 18C | 3055.8 (2378.5 to 3926.0) | 2183.9 (1686.9 to 2827.3) |
| Serotype: 19A | 219.3 (169.4 to 283.9) | 275.7 (212.0 to 358.6) |
| Serotype: 19F | 236.1 (191.6 to 291.1) | 272.7 (219.1 to 339.4) |
| Serotype: 23F | 1036.4 (746.9 to 1438.0) | 926.8 (673.9 to 1274.7) |
Antibody-mediated serum OPA against the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a pneumococcal OPA assay. Initial results were measured as OPA titers, which were then logarithmically transformed for analysis; geometric means calculated and expressed as GMTs.
| titer (1/dilution) | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Serotype: 1 | 204.2 (164.7 to 253.3) | 217.0 (176.4 to 266.9) |
| Serotype: 3 | 121.0 (104.4 to 140.3) | 129.8 (111.7 to 150.8) |
| Serotype: 4 | 2991.4 (2437.5 to 3671.3) | 2519.0 (2098.7 to 3023.6) |
| Serotype: 5 | 157.6 (131.9 to 188.3) | 153.4 (126.6 to 185.8) |
| Serotype: 6A | 2945.7 (2376.0 to 3652.1) | 3092.5 (2493.5 to 3835.4) |
| Serotype: 6B | 1948.9 (1521.4 to 2496.7) | 1750.1 (1360.9 to 2250.8) |
| Serotype: 7F | 4161.5 (3498.0 to 4950.9) | 4353.8 (3706.5 to 5114.0) |
| Serotype: 9V | 6927.5 (5765.9 to 8323.2) | 6460.4 (5277.3 to 7908.7) |
| Serotype: 14 | 1505.8 (1246.5 to 1819.0) | 1302.2 (1106.1 to 1533.2) |
| Serotype: 18C | 8028.3 (6233.7 to 10339.7) | 7830.0 (5998.5 to 10220.7) |
| Serotype: 19A | 1848.9 (1472.0 to 2322.2) | 1832.5 (1454.9 to 2308.1) |
| Serotype: 19F | 808.0 (633.0 to 1033.5) | 766.0 (609.2 to 963.2) |
| Serotype: 23F | 3125.0 (2450.8 to 3984.7) | 3348.8 (2639.5 to 4248.5) |
Percentage of participants achieving OPA titer \>=LLOQ along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of participants was presented. LLOQ (measured in mcg/mL) for each serotype is as follows: Serotype 1=18; Serotype 3=12; Serotype 4=21; Serotype 5=29; Serotype 6A=37; Serotype 6B=43; Serotype 7F=113; Serotype 9V=141; Serotype 14=35; Serotype 18C=31; Serotype 19A=18; Serotype 19F=48; Serotype 23F=13.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Serotype: 1 | 51.4 (41.7 to 61.0) | 46.2 (36.5 to 56.2) |
| Serotype: 3 | 98.2 (93.5 to 99.8) | 98.1 (93.4 to 99.8) |
| Serotype: 4 | 98.1 (93.3 to 99.8) | 99.0 (94.6 to 100.0) |
| Serotype: 5 | 62.3 (52.7 to 71.2) | 62.6 (52.7 to 71.8) |
| Serotype: 6A | 91.2 (84.3 to 95.7) | 94.4 (88.2 to 97.9) |
| Serotype: 6B | 94.5 (88.4 to 98.0) | 92.3 (85.4 to 96.6) |
| Serotype: 7F | 99.0 (94.3 to 100.0) | 96.8 (90.9 to 99.3) |
| Serotype: 9V | 88.3 (80.5 to 93.8) | 88.0 (80.0 to 93.6) |
| Serotype: 14 | 82.9 (74.6 to 89.4) | 76.9 (67.8 to 84.4) |
| Serotype: 18C | 98.1 (93.2 to 99.8) | 98.0 (92.9 to 99.8) |
| Serotype: 19A | 92.1 (85.0 to 96.5) | 95.7 (89.2 to 98.8) |
| Serotype: 19F | 89.7 (82.3 to 94.8) | 91.4 (84.4 to 96.0) |
| Serotype: 23F | 94.9 (88.6 to 98.3) | 94.9 (88.5 to 98.3) |
Percentage of participants achieving OPA titer \>=LLOQ along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of participants was presented. LLOQ (measured in mcg/mL) for each serotype is as follows: Serotype 1=18; Serotype 3=12; Serotype 4=21; Serotype 5=29; Serotype 6A=37; Serotype 6B=43; Serotype 7F=113; Serotype 9V=141; Serotype 14=35; Serotype 18C=31; Serotype 19A=18; Serotype 19F=48; Serotype 23F=13.
| percentage of participants | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) |
|---|---|---|
| Serotype: 1 | 97.1 (91.9 to 99.4) | 97.1 (91.6 to 99.4) |
| Serotype: 3 | 98.1 (93.4 to 99.8) | 100.0 (96.4 to 100.0) |
| Serotype: 4 | 100.0 (96.4 to 100.0) | 100.0 (96.3 to 100.0) |
| Serotype: 5 | 95.2 (89.2 to 98.4) | 97.1 (91.6 to 99.4) |
| Serotype: 6A | 100.0 (96.5 to 100.0) | 99.0 (94.6 to 100.0) |
| Serotype: 6B | 97.0 (91.6 to 99.4) | 95.0 (88.8 to 98.4) |
| Serotype: 7F | 100.0 (96.3 to 100.0) | 100.0 (96.0 to 100.0) |
| Serotype: 9V | 100.0 (96.4 to 100.0) | 99.0 (94.4 to 100.0) |
| Serotype: 14 | 100.0 (96.6 to 100.0) | 100.0 (96.4 to 100.0) |
| Serotype: 18C | 99.0 (94.6 to 100.0) | 99.0 (94.6 to 100.0) |
| Serotype: 19A | 100.0 (96.3 to 100.0) | 99.0 (94.3 to 100.0) |
| Serotype: 19F | 96.1 (90.3 to 98.9) | 97.0 (91.4 to 99.4) |
| Serotype: 23F | 99.0 (94.7 to 100.0) | 99.0 (94.3 to 100.0) |
Collected over Infant series: SAEs and non-SAEs= from Vaccination 1 up to 1 month post Vaccination 3 (for 3 months). Between infant series and toddler dose: SAEs:1 month post Vaccination 3 up to pre-vaccination 4 (for 7.5 months), non-SAEs were not planned to be collected. Toddler dose: SAEs and non-SAEs = up to 1 month post Vaccination 4 (for 1 month). Local reactions and systemic events =7 days post any vaccination (systematic assessment). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC, MDV With Preservative: Infant Series | 0/150 (0%) | 5/150 (3.3%) | 145/150 (96.7%) |
| 13vPnC, PFS Without Preservative: Infant Series | 0/150 (0%) | 4/150 (2.7%) | 141/150 (94%) |
| 13vPnC, MDV: Between Infant Series and Toddler Dose | 0/150 (0%) | 6/150 (4%) | — |
| 13vPnC, PFS: Between Infant Series and Toddler Dose | 0/150 (0%) | 3/150 (2%) | — |
| 13vPnC, MDV With Preservative: Toddler Dose | 0/139 (0%) | 1/139 (0.7%) | 58/139 (41.7%) |
| 13vPnC, PFS Without Preservative: Toddler Dose | 0/139 (0%) | 0/139 (0%) | 54/139 (38.8%) |
| Event | 13vPnC, MDV With Preservative: Infant Series | 13vPnC, PFS Without Preservative: Infant Series | 13vPnC, MDV: Between Infant Series and Toddler Dose | 13vPnC, PFS: Between Infant Series and Toddler Dose | 13vPnC, MDV With Preservative: Toddler Dose | 13vPnC, PFS Without Preservative: Toddler Dose |
|---|---|---|---|---|---|---|
| BronchiolitisInfections and infestations | 4/150 | 2/150 | 0/150 | 0/150 | 0/139 | 0/139 |
| SeizureNervous system disorders | 0/150 | 2/150 | 1/150 | 0/150 | 0/139 | 0/139 |
| Escherichia urinary tract infectionInfections and infestations | 0/150 | 0/150 | 0/150 | 0/150 | 1/139 | 0/139 |
| Febrile convulsionNervous system disorders | 0/150 | 0/150 | 1/150 | 0/150 | 1/139 | 0/139 |
| AnaemiaBlood and lymphatic system disorders | 0/150 | 1/150 | 0/150 | 0/150 | 0/139 | 0/139 |
| Lower respiratory tract infectionInfections and infestations | 1/150 | 0/150 | 1/150 | 1/150 | 0/139 | 0/139 |
| Urinary tract infectionInfections and infestations | 0/150 | 1/150 | 1/150 | 0/150 | 0/139 | 0/139 |
| Lower respiratory tract infection viralInfections and infestations | 0/150 | 0/150 | 1/150 | 0/150 | 0/139 | 0/139 |
| Viral infectionInfections and infestations | 0/150 | 0/150 | 1/150 | 0/150 | 0/139 | 0/139 |
| CellulitisInfections and infestations | 0/150 | 0/150 | 0/150 | 1/150 | 0/139 | 0/139 |
| Event | 13vPnC, MDV With Preservative: Infant Series | 13vPnC, PFS Without Preservative: Infant Series | 13vPnC, MDV: Between Infant Series and Toddler Dose | 13vPnC, PFS: Between Infant Series and Toddler Dose | 13vPnC, MDV With Preservative: Toddler Dose | 13vPnC, PFS Without Preservative: Toddler Dose |
|---|---|---|---|---|---|---|
| Injection site pain-2General disorders | 117/150 | 125/150 | — | — | 33/139 | 26/139 |
| IrritabilityPsychiatric disorders | 114/150 | 117/150 | — | — | 32/139 | 31/139 |
| Hypersomnia (Increased sleep)Nervous system disorders | 105/150 | 116/150 | — | — | 10/139 | 25/139 |
| Decreased appetiteMetabolism and nutrition disorders | 92/150 | 107/150 | — | — | 20/139 | 22/139 |
| SwellingGeneral disorders | 64/150 | 70/150 | — | — | 12/139 | 16/139 |
| Erythema (Redness)Skin and subcutaneous tissue disorders | 52/150 | 49/150 | — | — | 11/139 | 15/139 |
| Injection site pain-1General disorders | 44/150 | 46/150 | — | — | 0/139 | 0/139 |
| Pyrexia-2General disorders | 37/150 | 32/150 | — | — | 0/139 | 0/139 |
| Injection site swellingGeneral disorders | 17/150 | 16/150 | — | — | 0/139 | 0/139 |
| Upper respiratory tract infectionInfections and infestations | 16/150 | 10/150 | — | — | 0/139 | 0/139 |
Safety population included all participants who received at least 1 dose of study vaccine.
| Age, Continuous(Weeks) | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) | Total |
|---|---|---|---|
| Mean | 6.9 ± 0.95 | 6.9 ± 0.99 | 6.9 ± 0.97 |
| Sex: Female, Male(Participants) | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) | Total |
|---|---|---|---|
| Female | 74 | 67 | 141 |
| Male | 76 | 83 | 159 |
| Ethnicity (NIH/OMB)(Participants) | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 150 | 150 | 300 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 13vPnC: Multi-dose Vial (With Preservative) | 13vPnC: Single-dose Prefilled Syringe (Without Preservative) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 150 | 150 | 300 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2018 to primary completion in Dec 2019, 18 months.
Results were first posted in Sep 2020, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine